Actively Recruiting
Evaluation of the Impact of Electronic Monitoring on Patient Compliance in Hematology
Led by Private Hospital of Confluent, France · Updated on 2025-06-13
110
Participants Needed
3
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Management of hemopathies has progressed with the arrival of new drugs such as CAR T-cells (Chimeric Antigen Receptor T-cells), immunotherapy and targeted therapies, while increasing emphasis is being placed on outpatient care. The emergence of oral therapies has simplified the treatment pathway, but they are not without their undesirable effects, which can sometimes lead to treatment suspension or even discontinuation. These undesirable effects may be related either to the haemopathy (pain, general signs, fatigue, malnutrition, infection, etc.), or to the toxicity of the treatments, or to co-morbidities. It is therefore essential to detect and manage these adverse effects in real time. In patients treated with oral therapy, poor compliance (\<80% of doses taken) can have a direct impact on progression-free survival and sometimes on overall survival (Dashputre et al, Williams et al). It is therefore imperative for patients to follow prescribed treatments correctly, and for doctors to check for the absence of side-effects that could adversely affect patient safety and quality of life. Monitoring of these side effects varies from one center to another: it can be "classic", with a call from the patient or GP in the event of an event; it can be telephone-based (AMA-type coordination nurse for Ambulatory Medical Assistance); and finally, it can be electronic via a remote monitoring application. Monitoring by electronic application has been evaluated in oncology, with a benefit on early detection of side effects or signs of disease progression The human resources and organization of hematology departments are highly heterogeneous, and few studies have been carried out for patients treated long-term (≥ 6 months) with oral therapy. For these patients, therapeutic compliance is one of the parameters to be assessed, in order to optimize dose-intensity and duration of response. We propose here to compare two types of follow-up for patients due to start oral therapy: standard follow-up and follow-up by electronic application (Cureety).
CONDITIONS
Official Title
Evaluation of the Impact of Electronic Monitoring on Patient Compliance in Hematology
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Follow-up for hemopathy requiring oral therapy lasting more than 6 months (first line or more)
- Intravenous treatments allowed alongside oral therapy as per guidelines
- Patient must be affiliated with a social security scheme
- Patient must provide written consent before study procedures
You will not qualify if you...
- Oral treatment expected to last less than 6 months
- Brain tumor involvement
- Other active cancer within 3 years, except certain skin, prostate, and cervical cancers treated only by surgery
- Pregnancy or breastfeeding
- Persons deprived of liberty or under legal guardianship
- Dementia, mental illness, or psychiatric conditions affecting consent or compliance
- Inability to participate due to psychological, social, family, or geographic reasons
- No internet connection
- No telephone line
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Clinique de l'Europe
Amiens, France, 80090
Actively Recruiting
2
Clinique de la Baie
Morlaix, France, 29672
Actively Recruiting
3
Hôpital Privé du Confluent
Nantes, France, 44000
Actively Recruiting
Research Team
K
Katell Le Dû, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here